These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 36243370

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
    Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS.
    Nat Commun; 2017 Feb 14; 8():14454. PubMed ID: 28195574
    [Abstract] [Full Text] [Related]

  • 4. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B, Wood MJA, Roberts TC.
    RNA Biol; 2021 Jul 14; 18(7):1048-1062. PubMed ID: 33472516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System.
    Zhang Y, Bassel-Duby R, Olson EN.
    Methods Mol Biol; 2023 Jul 14; 2587():411-425. PubMed ID: 36401041
    [Abstract] [Full Text] [Related]

  • 8. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.
    Alizadeh F, Abraghan YJ, Farrokhi S, Yousefi Y, Mirahmadi Y, Eslahi A, Mojarrad M.
    Mol Cell Biochem; 2024 May 14; 479(5):1027-1040. PubMed ID: 37289342
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M, Xu L, Gao Y, Canan BD, Adesanya TMA, Warner SC, Akagi K, Symer DE, Mohler PJ, Ma J, Janssen PML, Han R.
    Circ Res; 2017 Sep 29; 121(8):923-929. PubMed ID: 28790199
    [Abstract] [Full Text] [Related]

  • 11. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
    Happi Mbakam C, Lamothe G, Tremblay G, Tremblay JP.
    Neurotherapeutics; 2022 Apr 29; 19(3):931-941. PubMed ID: 35165856
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
    Wasala NB, Million ED, Watkins TB, Wasala LP, Han J, Yue Y, Lu B, Chen SJ, Hakim CH, Duan D.
    Hum Gene Ther; 2022 May 29; 33(9-10):518-528. PubMed ID: 35350865
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T, Lau YS, Liu D, Liu T, Xu L, Gao Y, Lai L, Li Z, Han R.
    Dis Model Mech; 2018 Jun 04; 11(6):. PubMed ID: 29871865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
    Pini V, Mariot V, Dumonceaux J, Counsell J, O'Neill HC, Farmer S, Conti F, Muntoni F.
    Sci Rep; 2022 Mar 08; 12(1):3756. PubMed ID: 35260651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.